Bayer
Ginkgo Bioworks to Acquire Zymergen for $300M in Stock
Separately, Ginkgo said it will acquire Bayer's West Sacramento, California R&D site for $83 million and has entered a multi-year collaboration with the firm.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection
The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib).
Ginkgo Bioworks Q1 Revenues More Than Triple
The Boston-based synthetic biology and biosecurity firm beat the consensus Wall Street revenue estimate but missed on the bottom line.
Precision Cancer Consortium Launches With Bayer, GSK, Roche, Novartis as Founding Members
The organization of pharmaceutical and biotechnology firms aims to increase access to genomic testing for cancer patients.